Aura Biosciences, Inc.
AURA
$5.36
-$0.04-0.74%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.54% | 22.45% | 14.10% | 4.41% | 1.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.20% | 13.39% | 12.26% | 14.76% | 40.71% |
| Operating Income | -12.20% | -13.39% | -12.26% | -14.76% | -40.71% |
| Income Before Tax | -17.35% | -13.43% | -11.14% | -12.56% | -32.82% |
| Income Tax Expenses | -82.48% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.73% | -13.67% | -11.14% | -12.82% | -33.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.73% | -13.67% | -11.14% | -12.82% | -33.65% |
| EBIT | -12.20% | -13.39% | -12.26% | -14.76% | -40.71% |
| EBITDA | -12.50% | -13.77% | -12.38% | -15.12% | -41.46% |
| EPS Basic | -4.38% | 12.60% | 15.10% | 13.80% | 4.19% |
| Normalized Basic EPS | -3.93% | 12.77% | 15.09% | 13.98% | 1.99% |
| EPS Diluted | -4.38% | 12.60% | 15.10% | 13.80% | 4.19% |
| Normalized Diluted EPS | -3.93% | 12.77% | 15.09% | 13.98% | 1.99% |
| Average Basic Shares Outstanding | 11.84% | 30.06% | 30.89% | 30.88% | 39.49% |
| Average Diluted Shares Outstanding | 11.84% | 30.06% | 30.89% | 30.88% | 39.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |